Methodological Considerations in Evaluation of Cancer as an Adverse Outcome Associated With Use of Non-Oncological Drugs and Biological Products in the Postapproval Setting; Public Meeting; Request for Comments, 34315-34317 [2014-13907]
Download as PDF
<![CDATA[
emcdonald on DSK67QTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 115 / Monday, June 16, 2014 / Notices
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
and the United States. The six ICH
sponsors are the European Commission;
the European Federation of
Pharmaceutical Industries Associations;
the Japanese Ministry of Health, Labour,
and Welfare; the Japanese
Pharmaceutical Manufacturers
Association; CDER, CBER, and FDA;
and the Pharmaceutical Research and
Manufacturers of America. The ICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation of Pharmaceutical
Manufacturers Associations (IFPMA).
The ICH Steering Committee includes
representatives from each of the ICH
sponsors and the IFPMA, as well as
observers from the World Health
Organization, Health Canada, and the
European Free Trade Area.
In the Federal Register of February
17, 2009 (74 FR 7449), FDA published
a notice announcing the availability of
a draft guidance entitled ‘‘Q4B
Evaluation and Recommendation of
Pharmacopoeial Texts for Use in the
ICH Regions; Annex 6: Uniformity of
Dosage Units General Chapter.’’ The
notice gave interested persons an
opportunity to submit comments by
April 20, 2009.
After consideration of the comments
received and revisions to the guidance,
a final draft of the guidance was
submitted to the ICH Steering
Committee and endorsed by the three
participating regulatory agencies in
November 2013.
The guidance provides the specific
evaluation results from the ICH Q4B
process for the Uniformity of Dosage
Units General Chapter harmonized text
originating from the three-party PDG.
This guidance is in the form of an annex
to the core ICH Q4B guidance (https://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/
UCM073405.pdf) made available in the
Federal Register of February 21, 2008
(73 FR 9575). The annex will provide
guidance to assist industry and
regulators in the implementation of the
specific topic evaluated by the ICH Q4B
process.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on this topic. It does
VerDate Mar<15>2010
16:36 Jun 13, 2014
Jkt 232001
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
II. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm, or
https://www.regulations.gov.
Dated: June 10, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–13908 Filed 6–13–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0731]
Methodological Considerations in
Evaluation of Cancer as an Adverse
Outcome Associated With Use of NonOncological Drugs and Biological
Products in the Postapproval Setting;
Public Meeting; Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug Administration
(FDA), in collaboration with the
National Cancer Institute (NCI), is
announcing a public meeting entitled
‘‘Methodological Considerations in
Evaluation of Cancer as an Adverse
Outcome Associated With Use of NonOncological Drugs and Biological
Products in the Postapproval Setting.’’
The purpose of the public meeting is to
engage in constructive dialogue and
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
34315
information sharing among regulators,
researchers, the pharmaceutical
industry, public health agencies, health
care providers, and the general public
concerning challenges in designing and
implementing postapproval studies to
evaluate the risk of cancer associated
with use of non-oncological drugs and
biological products. The input from this
meeting and public docket will be used
to inform the Agency on best study
design and methodological options to
consider when evaluating cancer risk in
the postapproval setting.
Dates and Time: The public meeting
will be held on September 10, 2014,
from 8 a.m. to 5 p.m., and September 11,
2014, from 8 a.m. to 5 p.m.
Location: The public meeting will be
held at The DoubleTree by Hilton Hotel
Washington DC—Silver Spring, The
Maryland Ballroom, 8727 Colesville Rd.,
Silver Spring, MD 20910 (Metro: Silver
Spring Station on the Red Line).
Contact Person: Paul Tran, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–9029, FAX: 301–
796–9832, Paul.Tran@fda.hhs.gov.
Registration and Requests for Oral
Presentations: Registration is free and
available on a first-come, first-served
basis. You must register online by
August 27, 2014. Seating is limited, so
register early. FDA may limit the
number of participants from each
organization. If time and space permit,
onsite registration on the day of the
meeting will be available. To register for
this meeting, please visit FDA’s Drugs
News & Events—Meetings, Conferences,
& Workshops calendar at https://
www.fda.gov/Drugs/NewsEvents/
ucm132703.htm and select this meeting
from the events list. If you need special
accommodations due to a disability,
please contact Paul Tran (see Contact
Person) by September 3, 2014. Those
without Internet access should contact
Paul Tran to register.
This meeting includes a public
comment session. If you would like to
present at the meeting on topics related
to challenges in designing and
implementing postapproval studies to
evaluate the risk of cancer associated
with use of non-oncological drugs and
biological products, please identify
during registration the topic(s) you will
address (see section II).
FDA will do its best to accommodate
requests to speak. FDA urges
individuals and organizations with
common interests to coordinate and give
a joint, consolidated presentation.
Following the close of registration, FDA
will allot time for each presentation and
notify presenters by September 3, 2014.
E:\FR\FM\16JNN1.SGM
16JNN1
34316
Federal Register / Vol. 79, No. 115 / Monday, June 16, 2014 / Notices
emcdonald on DSK67QTVN1PROD with NOTICES
Do not present or distribute commercial
or promotional material during the
meeting. Registered presenters should
check in before the meeting.
Comments: FDA is holding this
meeting to seek input on the study
design and methodological options for
conducting postapproval studies to
evaluate cancer as an adverse outcome
associated with use of non-oncological
drugs and biological products. FDA is
soliciting from interested persons
electronic or written comments on all
aspects of the meeting topics through
October 9, 2014.
Attendees and non-attendees may
submit electronic comments to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. Send only
one set of comments. When sending
comments, please include the docket
number from the heading of this notice.
In addition, when addressing specific
topics (see section II), please identify
the topic. Received comments may be
viewed in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday, and will be
posted to the docket at https://
www.regulations.gov.
Transcripts: After the meeting, FDA
will post a transcript at https://
www.regulations.gov. The transcript
may be viewed at the Division of
Dockets Management (see Comments). A
transcript will also be available in either
hardcopy or on CD–ROM upon
submission of a Freedom of Information
request. Send requests to the Division of
Freedom of Information (ELEM–1029),
Food and Drug Administration, 12420
Parklawn Dr., Element Bldg., Rockville,
MD 20857.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is holding this meeting to seek
input from industry, academia, public
health agencies, the clinical community,
and other stakeholders regarding the
study design and methodological
options for conducting studies to
evaluate cancer as an adverse outcome
associated with use of non-oncological
drugs and biological products in the
postapproval setting.
Questions about whether a drug
causes or influences cancer
development and how this cancer risk
can be evaluated are frequent concerns
posed to FDA. Cancer signals can arise
from premarket non-clinical and clinical
trial data, and also from spontaneous
adverse event reports or other studies
conducted following a drug’s approval.
Unfortunately, further evaluation of
VerDate Mar<15>2010
16:36 Jun 13, 2014
Jkt 232001
these cancer signals is hindered by
methodological limitations of tools and
data available in the postapproval
setting, particularly in light of the often
complex exposure patterns and
expected long latency of certain cancer
outcomes. In the preapproval setting,
randomized controlled trials (RCTs) are
considered the gold standard in
evaluating drug efficacy, and can
evaluate frequently occurring and shortlatency adverse events. However, due to
certain limitations, RCTs are not best
suited to identify the occurrence of
cancer as an adverse outcome associated
with drug treatment, although cancer
events observed in trials raise concerns.
Preapproval RCTs have important
limitations, such as use of restricted
populations, limited number of
participants, as well as short duration
and followup time. Postapproval
studies, frequently observational, better
reflect real-world-use patterns and
capture the clinical experience for a
larger number of individuals over time.
In theory, these studies are better
positioned to evaluate rare and longerlatency drug safety signals, including
cancer signals. In practice, however,
evaluating drug-related cancer outcomes
using observational data is hampered by
important methodological limitations,
including difficulties in determining the
timing of the outcome occurrence
accurately, difficulties in identifying the
biologically relevant period of risk, and
challenges in handling complex
exposure patterns over time, among
others.
Given the many methodological
challenges in the postmarketing
evaluation of adverse cancer outcomes
associated with use of non-oncological
products and current gaps in
knowledge, FDA, in collaboration with
NCI, is sponsoring a public meeting to
seek input from industry, academia,
public health agencies, the clinical
community, and other stakeholders.
The meeting will include multiple
sessions over 2 days.
II. Scope of the Meeting
The objective of the meeting is to
engage researchers, industry, public
health agencies, health care providers,
and the public through presentations
and panel discussions on the following
topics:
Topic 1: Determination of exposure
and identification of relevant risk
window. The ability to accurately
capture complex drug-use patterns over
a period of time, to determine the most
appropriate exposure metric(s), and to
identify the most biologically relevant
risk periods are essential elements in
the appropriate postapproval evaluation
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
of cancer-related outcomes associated
with use of non-oncological drugs and
biological products. There is currently
no consensus on how these elements
should be considered in postapproval
studies that evaluate cancer outcomes.
Discussions will explore methodologies
for determining informative exposure
metric(s), thresholds, latency period,
and length of followup. These
discussions will be based on current
knowledge of carcinogenesis, potential
underlying biological mechanisms, and
particular types of cancers (according to
site or histology). Given uncertainties
around defining some of these metrics,
discussions may consider strategies
beyond testing of hypotheses, including
the use of exploratory hypotheses and
sensitivity analyses, as well as
consideration of scenarios under which
postapproval studies are unlikely to be
informative.
Topic 2: Identification of cancerrelated outcome(s). The insidious nature
of cancer events makes identification
and timing-of-event occurrence
challenging. Discussions will focus on
relevant methodologies to identify
cancer-related outcomes, as well as
considerations regarding the challenges
involved in identifying the sequence of
symptoms that eventually lead to an
accurate cancer diagnosis, a sequence
that may be initiated before or during
drug exposure.
Topic 3: Identification of population/
data source. Identifying the relevant
characteristics of the data or population
source is crucial in conducting and
interpreting postapproval evaluations of
cancer signals. Discussions will focus
on the essential characteristics of
population/data source (e.g.
administrative databases, registries,
clinical encounters, surveys/interviews);
the ability to appropriately capture
medical history over time; and other
information relevant to the evaluation of
cancer outcomes, sample size, and
participant followup.
Topic 4: Current thinking on cancer
biology to inform epidemiology study
design. It is noteworthy that
recommendations for postapproval
study designs to date have been based
on the concept that cancer develops
over a period of time, long after
initiating drug treatment (long latency
period). Nonetheless, several cancerrelated signals have been observed
during preapproval RCTs of nononcological therapies, trials which
typically have short duration of
followup. Discussions will focus on the
current thinking of potential biological
mechanism(s) underlying purported
drug-related increase in initiating,
promoting, or detecting cancerous
E:\FR\FM\16JNN1.SGM
16JNN1
Federal Register / Vol. 79, No. 115 / Monday, June 16, 2014 / Notices
tumors, with particular consideration
given to scenarios where cancer signals
arise at any time following drug
exposure. Discussions will also focus on
cancer biology (and the different types
of tumors) to inform postapproval
evaluation of cancer signals and to
better identify the most relevant
exposure metric and risk windows.
Information about this meeting,
including registration and the agenda,
will be posted at https://www.fda.gov/
Drugs/NewsEvents/ucm132703.htm as it
becomes available.
Dated: June 10, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–13907 Filed 6–13–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
American Indians Into Psychology
Announcement Type: New and
Competing Continuation.
Funding Announcement Number:
HHS–2014–IHS–INPSY–0001.
Catalog of Federal Domestic
Assistance Number: 93.970.
Purpose
Key Dates
Application Deadline Date: July 18,
2014.
Review Date: July 28, 2014.
Earliest Anticipated Start Date:
September 01, 2014.
Proof of Non-Profit Status Due Date:
July 18, 2014.
I. Funding Opportunity Description
emcdonald on DSK67QTVN1PROD with NOTICES
Statutory Authority
The Indian Health Service (IHS)
Office of Public Health Support (OPHS)
is accepting competitive cooperative
agreement applications for the
American Indians into Psychology
Program (Section 217). This program is
authorized under Section 217 of the
Indian Health Care Improvement Act,
Public Law 94–437, as amended
(IHCIA), codified at 25 U.S.C. 1621p(a–
d). This program is described in the
Catalog of Federal Domestic Assistance
under 93.970.
Background
The IHS, an agency within the
Department of Health and Human
Services (HHS), is responsible for
providing Federal health services to
American Indians and Alaska Natives
(AI/AN). The mission of the IHS is to
raise the physical, mental, social, and
spiritual health of AI/AN. The IHCIA
VerDate Mar<15>2010
16:36 Jun 13, 2014
Jkt 232001
authorizes the IHS to administer
programs that are designed to attract
and recruit qualified individuals into
health professions needed at IHS
facilities. The programs administered
are designed to encourage AI/AN to
enter health professions and to ensure
the availability of health professionals
to serve AI/AN populations. Section 217
of the IHCIA requires IHS to administer
the American Indians into Psychology
Scholarship Program. Within the
Section 217 program, IHS provides
grants to colleges, universities, and
other entities to develop and maintain
psychology education programs and
recruit individuals to become Clinical
Psychologists who will provide services
to AI/AN people. Psychology program
scholarship grants may be used by the
educational institution to provide
scholarships to students enrolled in
clinical psychology education programs.
According to the terms and conditions
of the psychology program scholarship
grant award, scholarship awards are for
a 1-year period; additional scholarship
support may be awarded to each eligible
student for up to four years (maximum).
The purpose of this IHS cooperative
agreement is to augment the number of
Clinical Psychologists who deliver
health care services to AI/AN
communities. The primary objectives of
this cooperative agreement grant award
are to: (1) Recruit and train individuals
to be Clinical Psychologists; and (2)
Provide scholarships to individuals
enrolled in schools of clinical
psychology to pay tuition, books, fees,
and stipends for living expenses.
II. Award Information
Type of Award
Cooperative Agreement.
Estimated Funds Available
The total amount of funding
identified for the current fiscal year
2014 is approximately $715,078.
Individual award amounts are
anticipated to be between $200,000 and
$238,359. Awards issued under this
announcement are subject to the
availability of funds. In the absence of
funding, the IHS is under no obligation
to make awards that are selected for
funding under this announcement.
Anticipated Number of Awards
Approximately three awards will be
issued under this program
announcement.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
34317
Project Period
The project period will be for five
years and will run consecutively from
September 1, 2014 to August 31, 2019.
In the HHS, a cooperative agreement
is administered under the same policies
as a grant. The funding agency (IHS) is
required to have substantial
programmatic involvement in the
project during the entire award segment.
Below is a detailed description of the
level of involvement required for both
IHS and the grantee. IHS will be
responsible for activities listed under
section A and the grantee will be
responsible for activities listed under
section B as stated:
Substantial Involvement Description for
Cooperative Agreement
A. IHS Programmatic Involvement
(1) The IHS assigned program official
will work closely with the project’s
Principal Investigator/Project Director to
ensure timely receipt of the required
semi-annual progress reports from each
American Indians into Psychology
grantee and review them for program
compliance.
(2) The IHS assigned program official
will provide programmatic technical
assistance to the grantee as requested.
(3) The IHS assigned program official
will coordinate and conduct site visits
and semi-annual conference calls with
grantees and students.
(4) The IHS assigned program official
from the OPHS will work in partnership
with the Division of Grants Management
(DGM) to ensure all goals and objectives
of the proposed project are met.
(5) The IHS assigned program official
will provide an American Indians into
Psychology scholarship handbook for
student program review.
(6) The IHS assigned program official
will initiate default proceedings within
90 days after receiving notification from
the grantee that a student has been
dismissed from the program, withdrawn
from school, failed to graduate with a
Ph.D. in Clinical Psychology, or failed to
get licensed and begin obligated service
time within 90 days.
B. Grantee Cooperative Agreement
Award Activities
(1) The American Indians into
Psychology grantee must designate a
Principal Investigator/Project Director.
The Project Director is the individual
designated by the grant applicant to
manage the project or activity being
supported by the grant. He/she is
responsible for the scientific or
technical direction of the project, the
day-to-day management of the program,
and is accountable to the grantee for the
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 79, Number 115 (Monday, June 16, 2014)]
[Notices]
[Pages 34315-34317]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-13907]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0731]
Methodological Considerations in Evaluation of Cancer as an
Adverse Outcome Associated With Use of Non-Oncological Drugs and
Biological Products in the Postapproval Setting; Public Meeting;
Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA), in collaboration with the
National Cancer Institute (NCI), is announcing a public meeting
entitled ``Methodological Considerations in Evaluation of Cancer as an
Adverse Outcome Associated With Use of Non-Oncological Drugs and
Biological Products in the Postapproval Setting.'' The purpose of the
public meeting is to engage in constructive dialogue and information
sharing among regulators, researchers, the pharmaceutical industry,
public health agencies, health care providers, and the general public
concerning challenges in designing and implementing postapproval
studies to evaluate the risk of cancer associated with use of non-
oncological drugs and biological products. The input from this meeting
and public docket will be used to inform the Agency on best study
design and methodological options to consider when evaluating cancer
risk in the postapproval setting.
Dates and Time: The public meeting will be held on September 10,
2014, from 8 a.m. to 5 p.m., and September 11, 2014, from 8 a.m. to 5
p.m.
Location: The public meeting will be held at The DoubleTree by
Hilton Hotel Washington DC--Silver Spring, The Maryland Ballroom, 8727
Colesville Rd., Silver Spring, MD 20910 (Metro: Silver Spring Station
on the Red Line).
Contact Person: Paul Tran, Center for Drug Evaluation and Research,
Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring,
MD 20993-0002, 301-796-9029, FAX: 301-796-9832, Paul.Tran@fda.hhs.gov.
Registration and Requests for Oral Presentations: Registration is
free and available on a first-come, first-served basis. You must
register online by August 27, 2014. Seating is limited, so register
early. FDA may limit the number of participants from each organization.
If time and space permit, onsite registration on the day of the meeting
will be available. To register for this meeting, please visit FDA's
Drugs News & Events--Meetings, Conferences, & Workshops calendar at
https://www.fda.gov/Drugs/NewsEvents/ucm132703.htm and select this
meeting from the events list. If you need special accommodations due to
a disability, please contact Paul Tran (see Contact Person) by
September 3, 2014. Those without Internet access should contact Paul
Tran to register.
This meeting includes a public comment session. If you would like
to present at the meeting on topics related to challenges in designing
and implementing postapproval studies to evaluate the risk of cancer
associated with use of non-oncological drugs and biological products,
please identify during registration the topic(s) you will address (see
section II).
FDA will do its best to accommodate requests to speak. FDA urges
individuals and organizations with common interests to coordinate and
give a joint, consolidated presentation. Following the close of
registration, FDA will allot time for each presentation and notify
presenters by September 3, 2014.
[[Page 34316]]
Do not present or distribute commercial or promotional material during
the meeting. Registered presenters should check in before the meeting.
Comments: FDA is holding this meeting to seek input on the study
design and methodological options for conducting postapproval studies
to evaluate cancer as an adverse outcome associated with use of non-
oncological drugs and biological products. FDA is soliciting from
interested persons electronic or written comments on all aspects of the
meeting topics through October 9, 2014.
Attendees and non-attendees may submit electronic comments to
https://www.regulations.gov. Submit written comments to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD 20852. Send only one set of
comments. When sending comments, please include the docket number from
the heading of this notice. In addition, when addressing specific
topics (see section II), please identify the topic. Received comments
may be viewed in the Division of Dockets Management between 9 a.m. and
4 p.m., Monday through Friday, and will be posted to the docket at
https://www.regulations.gov.
Transcripts: After the meeting, FDA will post a transcript at
https://www.regulations.gov. The transcript may be viewed at the
Division of Dockets Management (see Comments). A transcript will also
be available in either hardcopy or on CD-ROM upon submission of a
Freedom of Information request. Send requests to the Division of
Freedom of Information (ELEM-1029), Food and Drug Administration, 12420
Parklawn Dr., Element Bldg., Rockville, MD 20857.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is holding this meeting to seek input from industry, academia,
public health agencies, the clinical community, and other stakeholders
regarding the study design and methodological options for conducting
studies to evaluate cancer as an adverse outcome associated with use of
non-oncological drugs and biological products in the postapproval
setting.
Questions about whether a drug causes or influences cancer
development and how this cancer risk can be evaluated are frequent
concerns posed to FDA. Cancer signals can arise from premarket non-
clinical and clinical trial data, and also from spontaneous adverse
event reports or other studies conducted following a drug's approval.
Unfortunately, further evaluation of these cancer signals is hindered
by methodological limitations of tools and data available in the
postapproval setting, particularly in light of the often complex
exposure patterns and expected long latency of certain cancer outcomes.
In the preapproval setting, randomized controlled trials (RCTs) are
considered the gold standard in evaluating drug efficacy, and can
evaluate frequently occurring and short-latency adverse events.
However, due to certain limitations, RCTs are not best suited to
identify the occurrence of cancer as an adverse outcome associated with
drug treatment, although cancer events observed in trials raise
concerns. Preapproval RCTs have important limitations, such as use of
restricted populations, limited number of participants, as well as
short duration and followup time. Postapproval studies, frequently
observational, better reflect real-world-use patterns and capture the
clinical experience for a larger number of individuals over time. In
theory, these studies are better positioned to evaluate rare and
longer-latency drug safety signals, including cancer signals. In
practice, however, evaluating drug-related cancer outcomes using
observational data is hampered by important methodological limitations,
including difficulties in determining the timing of the outcome
occurrence accurately, difficulties in identifying the biologically
relevant period of risk, and challenges in handling complex exposure
patterns over time, among others.
Given the many methodological challenges in the postmarketing
evaluation of adverse cancer outcomes associated with use of non-
oncological products and current gaps in knowledge, FDA, in
collaboration with NCI, is sponsoring a public meeting to seek input
from industry, academia, public health agencies, the clinical
community, and other stakeholders.
The meeting will include multiple sessions over 2 days.
II. Scope of the Meeting
The objective of the meeting is to engage researchers, industry,
public health agencies, health care providers, and the public through
presentations and panel discussions on the following topics:
Topic 1: Determination of exposure and identification of relevant
risk window. The ability to accurately capture complex drug-use
patterns over a period of time, to determine the most appropriate
exposure metric(s), and to identify the most biologically relevant risk
periods are essential elements in the appropriate postapproval
evaluation of cancer-related outcomes associated with use of non-
oncological drugs and biological products. There is currently no
consensus on how these elements should be considered in postapproval
studies that evaluate cancer outcomes. Discussions will explore
methodologies for determining informative exposure metric(s),
thresholds, latency period, and length of followup. These discussions
will be based on current knowledge of carcinogenesis, potential
underlying biological mechanisms, and particular types of cancers
(according to site or histology). Given uncertainties around defining
some of these metrics, discussions may consider strategies beyond
testing of hypotheses, including the use of exploratory hypotheses and
sensitivity analyses, as well as consideration of scenarios under which
postapproval studies are unlikely to be informative.
Topic 2: Identification of cancer-related outcome(s). The insidious
nature of cancer events makes identification and timing-of-event
occurrence challenging. Discussions will focus on relevant
methodologies to identify cancer-related outcomes, as well as
considerations regarding the challenges involved in identifying the
sequence of symptoms that eventually lead to an accurate cancer
diagnosis, a sequence that may be initiated before or during drug
exposure.
Topic 3: Identification of population/data source. Identifying the
relevant characteristics of the data or population source is crucial in
conducting and interpreting postapproval evaluations of cancer signals.
Discussions will focus on the essential characteristics of population/
data source (e.g. administrative databases, registries, clinical
encounters, surveys/interviews); the ability to appropriately capture
medical history over time; and other information relevant to the
evaluation of cancer outcomes, sample size, and participant followup.
Topic 4: Current thinking on cancer biology to inform epidemiology
study design. It is noteworthy that recommendations for postapproval
study designs to date have been based on the concept that cancer
develops over a period of time, long after initiating drug treatment
(long latency period). Nonetheless, several cancer-related signals have
been observed during preapproval RCTs of non-oncological therapies,
trials which typically have short duration of followup. Discussions
will focus on the current thinking of potential biological mechanism(s)
underlying purported drug-related increase in initiating, promoting, or
detecting cancerous
[[Page 34317]]
tumors, with particular consideration given to scenarios where cancer
signals arise at any time following drug exposure. Discussions will
also focus on cancer biology (and the different types of tumors) to
inform postapproval evaluation of cancer signals and to better identify
the most relevant exposure metric and risk windows.
Information about this meeting, including registration and the
agenda, will be posted at https://www.fda.gov/Drugs/NewsEvents/ucm132703.htm as it becomes available.
Dated: June 10, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-13907 Filed 6-13-14; 8:45 am]
BILLING CODE 4164-01-P
